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Abstract
The potential epidemiological  impact of preventive  HIV  Vaccines that convey  a high degree  of protection  in a
vaccines  on the HIV  epidemic in Southern  India  is  share of or all of those immunized  and that convey life-
examined  uSinig  a mathenmatical  deterministic  dynamic  long  immiiiunity are  the  most effective  in curbing  the HIV
compartmental  model.  Various assumptions  about the  epidemic.  Vaccines  that convey  less than complete
degree of protection  offered  by such a vaccine,  the extenit  protection  may also  have substantial  public health
of immilunological  response  of those vaccinated,  and the  impact,  but disinhibition can  easily  undo their effects and
duration  of protection  afforded  are explored.  Alternative  they should  be used combined  with  conventionial
targeting  strategies for HIV vaccinationi  are silulated  prevention efforts.  Conventional  intervenitions that
and compared  witlh  the  impact of convenitionial  target commercial  sex workers and their clients to
preventioni  interventionis  in higlh-risk  groups and  the  increase  condomil use  can  also be highly  effective  and can
general  population.  The impact of disinhibitioni  be implemenited  innmediately,  before  the arrival  of
(increased risk behavior  d(Ic  to the presence  of a vaccine)  vaccines.
is also considered.
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India's current HIV-1  seroprevalence rate of slightly less than 1 percent of
adults, or approximately  4 million HIV infected individuals,  is bound to increase.  In the
Southern states of India (Andhra Pradesh, Karnataka, Maharashtra and Tamil Nadu),
adult HIV- I prevalence of approximately  2 percent is already observed (National AIDS
Control Organisation website). In some districts, it is already over 4 percent.  The four
states together account for over 75 percent of all Indian HIV infections, even though
they have less than 30 percent of the adult population  (Government  of India 2002).  The
engine of the Indian epidemic is almost certainly heterosexual  transmission from
vulnerable groups, chiefly commercial  sex workers (CSWs) and their clients.
HIV infection in vulnerable groups has grown rapidly in India, where control of
HIV and sexually transmitted infections  (STI) used to be poor. The conditions for
further rapid growth are also in place: paid sex is common, rates of STI are high, male
mobility is high, rates of condom use in risky sex are low, and rates of male
circumcision-a presumed protective factor-are  low. Even an increase to a modest 5
percent infection  level in India, the lower end of the African epidemics,  in 2025, would
represent 25-30 million infected adults and, over the next 25 years, approximately  50
million cumulative HIV- I infections and 40 million cumulative  deaths. This is twice
the cumulative number of global deaths due to HIV/AIDS  over the past two decades.
This paper models the potential epidemiological  impact of preventive HIV
vaccines on the HIV/AIDS epidemic in Southern India, using a mathematical
deterministic dynamic  compartmental model.  In the second section, we describe the
basic assumptions  and workings of the model and the characteristics  of the vaccines
and targeting strategies  for an HIV vaccination campaign that are modeled. Various
assumptions  about the degree of protection offered by such a vaccine, the extent of
immunological  response in those vaccinated, and the duration of protection afforded
are explored.  In the third section, we present the results, comparing the epidemiological
impact of alternative vaccines and targeting strategies to that of conventional
prevention  strategies aimed at raising condom use among high-risk groups (sex workers
and their client) and improving the syndromic treatment of STIs. The impact of
disinhibition (increased  risk behavior due to the presence of a vaccine) is also
'considered. The final section summarizes  the results and points to implications for
HIV/AIDS prevention policies.
The best long-term hope for control of the HIV epidemic  may be a preventive
HIV vaccine.  Until one is developed,  scaling up high impact preventive interventions
can reduce the growth of the epidemic.  There is an urgent need to develop new
candidate vaccines,  but also a need to plan the considerable program requirements in
introducing new vaccines  and in fitting them into other prevention strategies.  An AIDS
vaccine will greatly help to reduce HIV/AIDS,  but it will not be a panacea.  Because of
the possibility of behavior reversals and an imperfect vaccine  (e.g., one that confersonly partial protection, or no protection at all in some of those vaccinated),  other
preventive  efforts must be continued, if not expanded.
2.  Methods
This paper complements a recent paper by Stover and others (2002) in which
two HIV/AIDS epidemiological  models (the Imperial College Model and IwgAIDS)
were used to explore the effects of a potential vaccine  in Thailand, Uganda,  and
Zimbabwe.  We extend a mathematical  model of HIV- I transmission  in Southern India,
using methods previously developed for Working Group Five of the Commission on
Macroeconomics  and Health (Nagelkerke and others 2002). We use the ModelMaker
program, version 3.0.3 (AP Benson 1993-97),  for implementing  our model.
The model
The model is a dynamic, deterministic  compartmental model.  The main features
of the model that are pertinent to the vaccine exercise are described in Figure  1. The
boxes represent compartments, or states, that individuals can be in and the arrows show
the flow of individuals between compartments.  Each compartment shown has been
implemented in duplicate, for men and women separately.  Individuals  move between
gender-specific compartments.  For example,  for women there are two groupings, CSW
and low-risk women. Each of these two groups  is split into several groups based on
their infection and immunization  status:
*  those uninfected and immunized,
*  those  uninfected and not immunized, and
*  those who are infected (in three sub-groups,  early stage, late state, and AIDS).
There  is no age structure in the model as used for the purpose of projecting the
impact of an HIV vaccine, with the exception that the model only concerns  the sexually
active adult population.'  It assumes that the epidemic  is primarily heterosexual,  driven
by commercial  sex, and that unsafe sex work is widespread and contributes
substantially to the spread of the infection. CSW and their clients were assigned
separate compartments  to reflect this assumption. In India, approximately  80 percent of
STI are first-generation  infections derived from sex work,  so this seems reasonable
(Rodrigues and others  1995).  Early female HIV infections occurred predominantly  in
CSW; infection in monogamous  women  is probably  linked to their husbands having
visited a CSW (Gangakhedkar and others  1997, Pais 1996).
1 The model also incorporates mother-to-child  transmission (MTCT,  "vertical transmission")  and an
intervention ("nevirapine")  to reduce this. However,  as we are mainly interested in adult prevalence,
which is not affected by MTCT, this is not considered here. A formal description of an earlier and more
complete version of the model is available on the Internet (Nagelkerke  and others 2001).
2Figure 1. Structure of the model
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Individuals are "born into" the low-risk uninfected category of their gender and
may move to and from high-risk groups (female CSWs and their male clients).  In
addition to dying from AIDS, they may die from other causes or "age" out of the
sexually active age group. High-risk groups may infect low-risk groups (e.g., their
current steady partners), including newly acquired low-risk (steady partners), for
example,  when they get married. The HIV disease process is broken down into three
stages:  early, late, and AIDS.2
The model includes neither transmission between men who have sex with men
(MSM) nor transmission due to intravenous drug use (IDU). Both occur in India, but it
is believed that they account for a minority of all transmissions.  The role of MSM and
IDU transmission and interaction with the heterosexual  epidemic may be small,
although IDU is an important mode of HIV transmission in the Northeastern state of
Manipur (the main exception).  Appendix 1 provides a formal technical description of
the model, including a graphical representation.
2 The three stages of AIDS in the model facilitate modeling the impact of anti-retroviral  therapy
(ART) targeted  at patients in different stages of HIV disease progression. ART  is not among the
interventions considered in this study, however.
3Parameters
In setting the parameters  of the model, demographic data from South India were
used where available;  otherwise data from whole of India were used. A recent study
conservatively  estimates that there are at least 2 million CSW in India, each having on
average-very conservatively-two  clients per day,  and that their clients number
approximately  30 million (i.e., slightly over  10 percent of the adult male population)
(Venkataramana and Sarada 2001). This suggests that each client may have some 50
CSW contacts annually. Based on the results of the recent nationwide behavioral
survey commissioned by the National AIDS Control Organization (NACO), on others'
estimates that over 40 percent of all CSWs work in the four Southern states, and on the
higher prevalence  of HIV in Southern  India, we assumed that approximately  20 percent
of all adult males are clients of CSW at any one time (NACO 2002).
Estimates of the rates of becoming a high-risk individual and transitioning back
to the low-risk category are not available. From the fact that most studies find the mean
age (and  age-range) of sex workers to be low (often around 23 years),  it follows that the
rate of leaving the profession must be high. We chose 20 percent annually for this rate.
We took half this value  for the transition rate of from client to non-client.  Rates of
becoming a client can then be derived from the number of clients and the rate of
becoming low-risk. For women we also introduced  a demand factor, i.e.,  low-risk
women's rate of becoming  a CSW was modeled as a function of the demand for sex
work.
The average duration  from infection to AIDS is the sum of the average duration
of the early and late stages;  we assumed four years in each of the two stages, resulting
in an average duration of HIV infection of eight years.
Modeling by the National Intelligence Council (2002)  has suggested that the
HIV/AIDS  epidemic in India, would result in up to 25 million people living with
HIV/AIDS by 2010,  i.e.,  an adult HIV prevalence of approximately 5 percent.
However, as Southern  India appears to be the worst-hit part of the subcontinent,  our
model corresponds to a scenario in which prevalence grows from its current level of
approximately 2 percent of the sexually  active population to an equilibrium prevalence
of almost 8 percent.
Table I gives the (baseline) parameters  used for the model: parameters were
chosen to reflect conditions in the four Southern  Indian states of Andhra Pradesh,
Karnataka,  Maharashtra,  and Tamil Nadu combined. With this choice of parameters,  a
2 percent HIV adult prevalence  in 2001 was obtained.  This prevalence would gradually
increase to 7.5  percent in 2033 in the absence of any interventions.  While not
comparable to the prevalence encountered  in many parts of Sub-Saharan  Africa, this
size of the epidemic would have devastating effects on Indian society and its socio-
economic development.
4Table 1. Model  parameters (no  interventions active)
Parameter  Description  (where relevant)  Value
aidsrate  Annual rate of developing AIDS from late stage HIV  0.25
Brate  Birth rate  0.085
cr_before  Contact rate between clients and CSW  50
Cust  Rate at which low-risk men become CSW-clients  0.04
Femgr  Rate of growth adult female population  0.021
Fmrisk  Female to male HIV transmission risk during CSW-client  0.0036
contact
HlVprog  Rate of  HIV progression  from early  to late stage  0.25
init_frac_cli  Initial (1998) fraction of adult men who are CSW clients  0.2
init_frac_csw  Initial (1998) fraction of adult women who are CSW  0.013
init_inf cli  Initial (1998)  clients HIV prevalence  0.07
init_inf_csw  Initial (1998)  CSW HIV prevalence  0.25
init_inf  fem  Initial (1998)  low-risk adult female HIV prevalence  0.005
init_inf_men  Initial (1998)  low risk adult males HIV prevalence  0.005
init_pop_female  Initial female adult population  70,000,000
init_pop_male  Initial male adult population  70,000,000
Leak  Transmission parameter high-risk to low-risk  0.075
loss_immun  Rate (annual) of loss of vaccine  induced immunity  0
Malegr  Rate of growth of adult male population  0.022
Marrate  Marriage rate  0.058
Mfrisk  Male to female HIV transmission  risk during CSW-client  0.0052
contact
Muaids  Death rate  AIDS patients  I
Muhiv_kids  Death rate  HIV infected children  0.25
Muneg  Death rate  HIV- adults  0.026
Mupos  Death rates (non-HIV) HIV+ adults  0.028
Prof  Parameter controlling proclivity of low risk women to become  0.004
Csw
stabfactor  Parameter on transmission between newly wed discordant  100
couples
Startyr_condom_CSW  Startyear (+1998)focussed  intervention among  CSW (use  35
condoms)
Startyrstd  Startyear (+1998) Mwanza style STI control  35
Startyr_vaccin  Startyear vaccine  intervention  35
STD_effect  Effect of STI control on transmission (I=no  effect,  0.7
0=transmission interrupted)
Uncust  Rate CSW clients become  low-risk men  0.1
Unprof  Rate CSW become low-risk women  0.2
Unprot_after  Level of CSW-client non-use of condoms after focused  0.25
intervention
Unprot_before  Same. Before intervention  0.5
Vaceff  Level of vaccine protection,  0= 100%,  1  = 0%  0
Vactake  Proportion of vaccinated who respond  0.5
Vtrate  Mother-to-child  (i.e. vertical) HIV transmission rate  0.33
wI  Relative  infectiousness  early stage HIV+  I
w2  Relative infectiousness  late stage HIV+  I
Note: The model  has additional parameters for estimating the impact of anti-retroviral  therapy; these are
not presented,  as they are not relevant to modeling the impact of an AIDS vaccine.
SVaccine characteristics
We compare the epidemiological impact over the period 1998-2033  of four
different vaccines, defined by the levels of two parameters:
*  Level ofprotection. The reduction in HIV susceptibility  in those giving an
effective immunological  response to the vaccine.  We consider two levels-50
percent and 100 percent.
*  Level of  immune response. The percentage of those vaccinated who have an
immunological  response to the vaccine.  We consider two levels-50 percent
and 95 percent-of those vaccinated. The vaccine has no protective effect on
the remaining 50 percent (or 5 percent)  receiving the vaccine who have no
immune response to it.
We use the term "vaccine efficacy"  to mean the product of the level of
protection and level of immune response-that is, the average protection  afforded to an
average vaccinated person. Thus, a vaccine of 50 percent average efficacy in the
population could be defined as either: (a) a vaccine conveying  100 percent protection to
half of those vaccinated (50 percent immune response); or (b) 50 percent protection to
everyone who is vaccinated  (100 percent immune response) or (c) some other
combination of protection  and immune response that yields an average  efficacy of 50
3 percent.
We assume that vaccines would become  available in 2008, which is the earliest
time vaccines would become  available for general use if current development efforts
prove successful, and that vaccines would provide (for those conferred any protection)
immunity for at least 25 years (or vaccine recipients  would be revaccinated sufficiently
often to simulate this duration of immunity).  In addition, we explored the effects of
waning of vaccine efficacy by showing the impact of the "best" vaccine considered
here (100  percent protection conferred to 95 percent of those vaccinated), if protection
lasted on average 3 years. Following loss of vaccine-induced  immunity, vaccine
recipients move back to the compartments  of susceptibles, from where they may be
recruited for vaccination again.
Targeting  strategies
We examine the impact of these vaccines  of differing levels of efficacy  using
two different targeting scenarios with different assumptions on coverage:
3 Stover and others (2002) refer to vaccines that convey 100 percent protection to a share of those
vaccinated  as "take" vaccines (example (a) in the text) and those that convey partial protection to all who
are vaccinated "degree"  vaccines (example (b) in the text). They show that the epidemiological  impact of
a vaccine  with a given average efficacy in a population is highly dependent on whether efficacy is
achieved through "take" or "degree."  This distinction between "take" and "degree" type effectiveness  is
not relevant for a vaccine  with 100 percent efficacy (that is, complete protection of  all who are
vaccinated),  as they are equivalent.  Stover and others do not model the impact of vaccines  with both
partial protection and partial immune response, such as example (c) in the text, though their impact
presumably would be somewhere between the impact of "take" and "degree"  type vaccines for a given
level of effectiveness.
6High risk group targeting  (HRG). Both CSWs and their clients are targeted.
Annually,  75 percent of those eligible  (i.e. belonging to the target population and not
yet immunized) would be vaccinated.  This would result  in an average coverage rate
(proportion of the groups vaccinated) of approximately 90 percent.
Population  targeting  (POP). Every sexually active adult is equally targeted
regardless of behavioral risk group. At the time the vaccine becomes available,  a 2-year
vaccination campaign is launched that succeeds  in reaching 25 percent of the target
population of susceptibles  (HIV negative, not immune) annually. This  is followed by
an indefinite period during which 5 percent of the target population is vaccinated
annually.  This leads to an equilibrium situation in which approximately  50 percent of
the sexually active population  has been vaccinated.  The initial 2-year vaccination
campaign  is included to reach that 50 percent coverage level quickly.
Conventional interventions  for comparison
As an HIV vaccine has not yet been developed and as a point of comparison, we
also modeled the epidemiological impact of two conventional  HIV prevention
interventions:
A focused CSW intervention. The objective of this intervention is to increase
condom use in CSW-client contacts.  Focused interventions have proven to be very
effective in increasing condom use in this context.  This reduces HIV transmission
among sex workers and clients, but also  in the general population, because of the
''core" role of these high-risk groups in spreading infection to the rest of the population
(Hethcote and York 1984, Jha and others 2001, World Bank 1997). Many peer-
mediated CSW intervention programs in India and Africa have shown increases  in
condom use of 80 percent or more among those reached (Bhave and others  1995, Jana
and others  1998, Jana and Singh  1995, Moses and others  1991). We conservatively
assumed that the intervention reduces the percentage of unprotected  contacts from 50 to
25 percent. We were also conservative  in not assuming an additional reduction in the
risk of transrnission per CSW-client  contact through a reduction in STI prevalence,
although this may well be the case.
Syndromic treatment of  STIs.  Epidemiological  studies support the hypothesis
that STIs are associated with increased HIV susceptibility and infectiousness.  However,
confounding makes  it difficult to reliably estimate these cofactor effects from
observational  studies (Korenromp and others 2001).  Three experimental  studies have
been carried out to date, one in Tanzania and two in Uganda.  STI management, through
improved treatment of patients with symptomatic  STI infections,  has proven to be
effective in a controlled community trial in Mwanza,  Tanzania, with an approximate 40
percent reduction in HIV transmission (Grosskurth and others  1995). STI management
was based on a syndromic approach to symptomatic cases. It was applied to a rural area
in a non-targeted way. People with asymptomatic  infections were not treated.  However,
the failure of a similar intervention  in a trial in Masaka, Uganda, to replicate  this
success (reported at the AIDS conference  in Barcelona),  and the lack of success in
7Rakai, Uganda,  to reduce HIV transmission through a program that offered mass
treatment for STIs to the population has sparked debate about the efficacy of such
interventions in slowing HIV transmission (Gray and others  1999, Hitchcock and
Fransen  1999, Hudson 2001, Korenromp  and others 2000, Kvale  1999, Matthys and
Boelaert  1999, Nicoll and others  1999). We nevertheless assumed for the purposes of
this modeling exercise that HIV transmission would decrease by 30 percent across the
board (males, females,  high-risk, low-risk). Arguably,  this is a strong simplification of
reality and requires averaging over partnerships with and without STI. In reality, the
average effect of the intervention may also vary among risk categories  (e.g., CSW and
other women), depending  on factors that are largely unknown, such as the uptake of the
intervention. No effects of the intervention  on sexual behavior were assumed. Note that
the way this 30 percent reduction is achieved  is irrelevant for our predictions.
Increasing condom use in the general population could be equally effective. As both
interventions use existing technologies, they were assumed to start in 2003.
Disinhibition  (increase  in risky behavior)
We explore whether disinhibition-that is, an increase in risky behavior
associated with the availability of an HIV vaccine-could nullify or reverse the impact
of the vaccine. Disinhibition has been observed  in high-risk gay men in response to the
availability of anti-retroviral  therapy (Katz and others 2002, Ostrow and others 2002,
Stolte and others 2001,  Stolte and Coutinho 2002). All models were run in the presence
of a strong disinhibition effect,  that is, assuming that condom use between CSWs and
clients dropped from 50 percent (assumed to have increased already  from very low
levels  in response to other prevention efforts) prior to the availability of vaccines to nil
(0 percent). For comparison (adult) HIV prevalence in 2033  (the last year of the
simulation) was used.
3.  Results
Table  2 shows the effect of the different interventions  on long run (2033) adult
HIV prevalence. Conventional prevention  programs begin in 2003  and vaccine
interventions  in 2008.
All vaccine scenarios  show a decline in HIV prevalence.  Generally, a high
degree of protection appears to be more important than a high "take"  rate. Disinhibition
(i.e. condoms are no longer used during CSW-clients) has the potential of undoing
much of the vaccine benefits, and may even aggravate  the epidemic. However, our
assumed extreme  disinhibition effect of total abandonment of condom use, may be
unlikely to happen,  as condoms  also provide protection against conventional  sexually
transmitted infections, an advantage  that CSWs may be keen to keep. Targeting high-
risk groups tends to be more effective than targeting the general population (at least at
the levels considered).  For the best vaccine considered (scenario 4), the impact appears
to be similar, perhaps due to "over-vaccination"  of high-risk groups (both clients and
CSWs have a high vaccine coverage).
8Table 2. Adult HIV prevalence in 2033 under seven scenarios, with and without
disinhibition'
Scenario  Adult HIV prevalence in 2033 (percent)
0  Baseline  7.5
Conventional  Protecton
interventions  (percent)
I  CSW condom  75b  1.4
intervention
2  STI syndromic treatment  30c  2.4
Targeted to high-risk groups  Targeted to general
Vaccine scenarios  Efficacy  (HRG)  population (POP)
(percent)  No  Disinhibitlon  No  Disnhibition
disinhibition  I disinhibitlon
3  100%  protection, 50%
response, 25 years  50  1.0  3.3  1.9  4.8
duration
4  100% protection,  95%
response, 25years  95  0.6  1.4  0.6  2.1
duratfon
5  50% protection, 95%
response, 25 years  47.5  2.9  9.5  3.2  8.5
duraton
6  50% protection, 50%
response,  25 years  25  3.7  10.3  4.6  10.0
duration
7  100% protection, 95%
response, 3 years  95  1.5  5.7  5.0  10.5
duraton
a.  Decline in condom use in commercial  sex from 50% to zero.
b.  Increase  in protection from 50% to 75% among  CSW-client contacts.
c.  Reduction in transmission probability.
Figures 2a and 2b show the impact of the different interventions  (without
disinhibition)  on HIV prevalence over the period 2003-2033.  Note that a highly
effective vaccine (scenario 4,  100 percent protection for 95 percent of those vaccinated)
appears to be by far the most effective method to bring down HIV prevalence quickly,
much faster than conventional prevention programs. The latter, however, have the
advantage that their implementation  could start immediately.
9Figure 2a. Epidemiological impact of targeting  a preventive HIV vaccine to the general
population, compared with CSW and STI interventions,  South India
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Figure 2b. Epidemiological  impact of targeting  a preventive HIV vaccine to the high-risk
population, compared with CSW and STI interventions,  South India
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Note: Vaccines target approximately  90 percent of CSWs and clients; scenarios defined in Table 2.
10Vaccine, condom, and  drug requirements
Figures 3a and 3b show the cumulative number of vaccinations  needed under
different strategies, assuming that those who are already HIV-positive are not
vaccinated.  Targeting high-risk groups typically requires substantially  fewer vaccine
doses than targeting the general population,  at a similar or higher impact. Thus, unless
the costs of targeting high risk groups are extremely high, targeting high-risk groups
should be typically several times more cost-effective than targeting the general
population. Also, to achieve reasonably high vaccination  coverage for the general
population, we assumed that a very intensive two-year vaccination campaign  would
"kick-start"  vaccination coverage. This would put enormous strains on production
facilities and other infrastructure  and may be difficult to implement.  The annual
number of vaccinations implied by each of the targeted and general population
strategies are in Table 3-including both the "kick-start"  phase and the "maintenance"
phase.
Costs follow from the costs to set up and maintain the infrastructure and of
course the cost per vaccination, at present unknown. Even targeting only high-risk
populations may require hundreds of  millions of vaccine doses over a 25-year period.
However, this is less than the number of childhood vaccinations given over that period
and, unless the vaccine is very expensive (over US$ 100, say), this would definitely
seem affordable.
The number of condoms needed for a focused intervention  for high-risk groups
is easy to calculate. We assumed that approximately  20 percent of sexually active adult
men would be clients, and that they have-on average-50 CSW contacts annually.
We (optimistically, but based on NACO's sexual behavior surveys) assumed that
approximately half of these contacts are already protected by condoms obtained  from
other sources (NACO 2002).  Thus, to increase condom use to 75 percent,  13 additional
condoms per client, or approximately 3 per adult male, would be required annually.
The amount of drugs and their costs for an STI control program are hard to
predict. In addition to current prevalence and incidence of STIs, knock-on effects in
terms of a reduction in transmission and a consequent decline in incidence  may yield
long-term savings in costs. For Mwanza, the annual per-capita costs of running am STI
program were estimated to be $0.39 (Gilson and others  1997).Figure 3a. Cumulative number of vaccinations  required for targeting the general
population, South India
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Figure 3b. Cumulative number of vaccinations  required for targeting high-risk groups,
South India
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12Table 3. Annual number of vaccinations  (millions),  by vaccination scenario
Year  3Pop  4Pop  5Pop  6Pop  7Pop  3HRG  4HRG  SHRG  6HRG  7HRG
2008  0  0  0  0  0  0  0  0  0  0
2009  36.75584  34.83045  34.83009  36.75562  35.24657  9.458652  8.191432  8.190107  9.4577  8.463783
2010  32.95754  28.07567  28.07135  32.95466  30.39358  7.024372  4.732682  4.723124  7.015272  5.880448
2011  6.244858  5.029587  5.026452  6.242568  6.04508  5.64389  3.323605  3.303129  5.61899  5.199646
2012  6.2351  4.984517  4.977201  6.229522  6.485979  4.86343  2.748514  2.718075  4.819448  5.084898
2013  6.231736  4.949949  4.936769  6.221292  6.808229  4.42484  2.514796  2.475336  4.3611  5.139177
2014  6.234492  4.924991  4.904447  6.217654  7.051646  4.181922  2.421921  2.374015  4.09868  5.24384
2015  6.243104  4.908842  4.879604  6.218406  7.242737  4.051666  2.387704  2.331829  3.949434  5.36314
2016  6.257324  4.900801  4.861685  6.223352  7.399158  3.986756  2.378304  2.314969  3.866054  5.486258
2017  6.276922  4.900245  4.850188  6.232322  7.53268  3.96011  2.379766  2.309487  3.821432  5.609946
2018  6.30168  4.906626  4.844663  6.245144  7.651148  3.95619  2.386378  2.309613  3.8  5.733307
2019  6.331402  4.919453  4.844703  6.261668  7.7598  3.966054  2.395833  2.312953  3.792784  5.856183
2020  6.3659  4.938289  4.849935  6.281744  7.862127  3.984578  2.407233  2.318507  3.794608  5.978658
2021  6.40501  4.962744  4.860026  6.305238  7.960466  4.008822  2.42026  2.325846  3.802472  6.100907
2022  6.448568  4.992467  4.874671  6.33202  8.056381  4.037122  2.434812  2.334781  3.814642  6.223128
2023  6.496434  5.027143  4.893588  6.36197  8.150922  4.068544  2.450875  2.345216  3.830102  6.345532
2024  6.548474  5.066488  4.916528  6.394974  8.244798  4.10257  2.468455  2.357095  3.848254  6.468314
2025  6.604564  5.110247  4.94326  6.430926  8.338489  4.138926  2.487564  2.370379  3.868744  6.591671
2026  6.66459  5.158189  4.973572  6.469724  8.432323  4.177472  2.508202  2.385034  3.891352  6.715784
2027  6.728448  5.210106  5.007272  6.511276  8.526526  4.21814  2.530365  2.401028  3.915942  6.840825
2028  6.796044  5.265813  5.044189  6.555494  8.621255  4.260894  2.554045  2.418331  3.942418  6.966954
2029  6.867288  5.325138  5.084162  6.602292  8.716624  4.30573  2.579222  2.436913  3.970718  7.094314
2030  6.942102  5.387928  5.127048  6.6516  8.812714  4.352646  2.605879  2.456742  4.000782  7.223042
2031  7.02041  5.454048  5.172717  6.703342  8.909587  4.401634  2.633994  2.477794  4.032574  7.353264
2032  7.102148  5.523376  5.221045  6.75745  9.007293  4.4527  2.66354  2.500041  4.066054  7.485094
2033  7.18726  5.595799  5.271928  6.813868  9.105866  4.505834  2.694497  2.523456  4.101184  7.618637
4.  Discussion
The HIV/AIDS epidemic in Southern India is more serious than that in most
other parts of India. Current adult HIV prevalence approximates  2 percent, and in the
absence of any intervention our model predicts a 7.5 percent adult HIV seroprevalence
in 2033. Unfortunately,  this prediction cannot be very precise as many model
parameters  are only approximately  known.
Our model suggests that all interventions considered are potentially able to
substantially  dent the HIV epidemic.  The effect of both highly effective vaccines  and of
a focused CSW intervention, based on condom promotion in which unprotected sex is
reduced by 50 percent, is impressive.  In the presence of a CSW intervention,
prevalence  would decline to  1.4 percent by 2033, less than the prevalence in 2001. This
is consistent with the finding (Gangakhedkar and others,  1997) that infections among
monogamous women in Pune (Maharashtra  state) arise mostly from their husband's
unprotected contact with sex workers.  Even in mature epidemics,  sex work is a key
source of new infections. For example,  adult prevalence in Cotonou, Benin, has
exceeded 3 percent for the last decade or more. Careful work by Lowndes and others
(2002) has concluded that virtually all of the ongoing HIV- I transmission is related to
13infection of female sex workers, male clients of female sex workers, and the other non-
regular sexual partners of those men.
Syndromic treatment of STIs would reduce HIV prevalence to 2.4 percent by
2033-not as impressive  as a CSW intervention, but still important.  It needs to be
stressed however, that the empirical basis for the impact of syndromic treatment of
STIs in India is less solid or well understood than that for focused CSW interventions,
especially  since preliminary results from the trial in Masaka, Uganda,  have come out.
Preventive HIV vaccines could be highly effective in controlling  the epidemic.
Early understanding of the immunology correlates of HIV- 1 protection,  and the genetic
variability  and rapid mutations of the HIV virus all suggest that a high efficacy vaccine
is unlikely at the outset, but could develop  with continuous testing (Esparza 2001,
Plummer and others 2001). A vaccine that conveys substantially  less than  full
protection to those who are immunized will not prevent sex workers from getting
infected, but would delay infection.  Thus, targeting vaccines with low protection to
high-risk groups is less effective than providing them with highly effective vaccines or
condom-based programs.  Moreover, sustained  condom use among high-risk groups
reduces transmission of STIs other than HIV.
Given a specified average vaccine  efficacy, vaccines would be most effective if
providing near  100 percent protection in to those who are immunized,  even if not
everyone vaccinated has an immunological response-in the terminology of Stover and
others  (2002), "take"-type efficacy.  Vaccines that confer the same average partial level
of protection to all vaccine recipients ("degree"-type efficacy) have less of an
epidemiological impact. This makes sense, as partial protection may be insufficient to
protect individuals with high-risk behaviors, although it would delay their infection.
This is consistent with findings by Stover and others (2002).
A vaccine that confers  100 percent protection in 95 percent of all vaccine
recipients could almost eradicate HIV within 25 years. Irrespective of the targeting
strategy (the general population or high-risk groups), adult HIV prevalence  would
shrink to a mere 0.6 percent in 2033 and would subsequently decline even further.
More importantly, this vaccine would still have a substantial  impact, even if CSW-
client condom use were to drop to zero (disinhibition). If high-risk populations  were
targeted with this highly effective  vaccine and condom use were to drop, adult HIV
prevalence in 2033 would be  1.4 percent; if the general population were targeted with
this vaccine and with disinhibition,  HIV prevalence would reach 2.1 percent.
The vaccine that would have the least effect is the vaccine that confers  50
percent protection to 50 percent of recipients-an average efficacy of only 25 percent.
Adult HIV prevalence would rise to 3.7 percent in 2033 if high risk groups are targeted,
while it would rise to 4.6 percent if the general population is targeted. The effects  of
this vaccine could be reversed by disinhibition, with adult HIV prevalence  in 2033 of
10.3 percent (if high-risk groups  are targeted) and  10.0 percent (population targeting),
respectively.  In other words, in the presence of disinhibition, HIV prevalence  in 2033
14would be 2.5-2.8 percentage points higher than the projected baseline, which reaches
7.5 percent in that time frame. This is also broadly consistent with findings by Stover
and others: "a vaccine with low efficacy  and low duration could have negative impact
on public health if its implementation were accompanied by widespread reversion to
riskier sexual behaviors"  (p. 29). They conclude that "with low efficacy vaccines it will
be very important to support the vaccination program with efforts to combat any
reversal to riskier sex. If efforts to maintain safer sex behaviors are not successful, then
behavioral reversals could eliminate most of the benefits of the vaccine.  In some cases
the effect could be to increase HIV incidence" (p. 29).
Whether disinhibition  is a likely scenario is unknown. It seems to be largely
based on the experience  with anti-retroviral therapy. While a vaccine may have the
same effect,  a vaccination  campaign may also raise HIV awareness in the population
and increase a sense of vulnerability in unvaccinated  individuals.  A sense of
invulnerability in vaccinated individuals would only be a problem in partially effective
vaccines.
Aside from effectiveness, there is the issue of the cost and feasibility  of
interventions.  Interventions share infrastructure costs (e.g., surveillance costs would be
used for both types of program). Large population laboratories  are needed to support
new generations of vaccine testing and newer intervention research on interventions for
high-risk groups. These costs are often of the nature  of  joint costs.  Costs for preventing
HIV growth have to be integrated  with costs of other interventions.  For example,
outreach campaigns for vaccines would probably aim to deliver several vaccines,
including those for childhood vaccine preventable  diseases.
The assumed vaccination coverage rates, while not 100 percent, even if
integrated  in existing structures, would still require substantial  efforts and costs, with
tens to hundreds of millions of vaccines administered over a 25-year period. A major
advantage of a preventive HIV vaccine, which it shares with CSW and STI
interventions,  is that a potential recipient is not required to take an HIV test as a
prerequisite for receiving a vaccine.  While vaccines given to HIV-positive adults are
clearly wasted (in the case of high-risk-group targeting this can be substantial),  a policy
of non-testing may be more efficient than one in which individuals are tested and
counseled. Nevertheless,  our estimates of the required number of vaccines only include
vaccines  for those who are HIV-negative.  For population targeting, the wastage of
vaccinating everybody is small. For high-risk populations, with a higher HIV
prevalence,  the wastage may be more substantial,  at least in relative terms. Targeting
high-risk groups is much more cost-effective  than targeting the entire adult population.
Using approximately  one third of the number of vaccines,  a higher reduction in
prevalence is achieved.  Although we did not explore this scenario, highly effective
vaccines could be targeted to CSW only (i.e., excluding their clients), as in the long run
this would be almost as effective as protecting both CSW and their clients. Vaccinating
both CSWs and their clients would  in the long run lead to substantial redundancy in
15prevention efforts.  By contrast, for vaccines conferring partial protection or with a low
"take" rate it would seem sensible to vaccinate  both CSWs and their clients.
Conventional HIV prevention programs, especially those targeting CSWs
(focused interventions) and using existing low-tech methods, may achieve results that
are similar to reasonably effective vaccines and are probably less sensitive to
disinhibition effects. It would therefore seem wise not to wait for the arrival of a
vaccine, but to implement and expand focused CSW prevention programs as early and
vigorously as possible. This will also create the infrastructure  for effectively
introducing HIV vaccines into these groups as soon as vaccines become available, and
for scaling up vaccination campaigns.  Such programs, however, require the political
will to initiate and sustain them. Political support for vaccination campaigns,  even for
partially effective vaccines, may come easy, perhaps more so than for programs
seemingly focusing on marginal groups such as CSWs.  In sum, for the next few years
expanding coverage of vulnerable group interventions while accelerating vaccine
research and strengthening capacity for both with surveillance, human resource
development, and operations  research are the best strategies to contain the Indian HIV-
1 epidemic.  When vaccines  become available  and particularly if efficacy or coverage is
not perfect (most likely they are not!), then "other prevention programs should continue
in conjunction with vaccination programs in order to reduce HIV infections to the
lowest possible levels  and maintain the other health benefits,  such as prevention of
sexually transmitted diseases" (Stover and others 2002, p.  30).
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ds_cli_s-mupos*AIDS_male+aids_men_r2+aids_cli_r2  Initial  Value = 0.0
Initial Value  = 0.0
csw_late_r2
ell_early r  dcsw  late  r2/dt = -mupos'csw  late_r2+prof8-
dcli_early_r/dt=-mupos*cli_early_r+custom3-  unprof8+res  cswout+res  c w_prog-aidcswcr2
uncustom3+inf  cli_r-pro_cli_r+inf_cli_immun  r  Initial Value = 0.0
Initial Value  = 0.0
csw_late_s
elI_earlys  adcsw_late_s/dt=-mupos*csw  late  s+prof4-
dcli_early  s/dt=-mupos*cli  earlys+custom2-  unprof4+procsws-artcswprog+artcswunprog-
uncustom2+inf  cli  s-pro_cli_s+inf_cli  immun_s  art_cw_out+art  _csw_unout-aids_csw_
Initial Value = init_pop_male*init_frac_ci*init_inf  cli*(l-  Initial Value =
hivprog/(aidsrate+hivprog)*hivprog/(hivprog+uncust))  initpopjfemale*init_frac-csw*mnit  inf csw*hivprogl(aids
cil immnun  rate+hivprog)*hivprog/(hivprog+unprof
dcl i_immun/dt= -munegcch_immun+custom0-  csw_out
uncustomO+immun_cli-inf  Ci_immun_r-inf  cli_immun_s-  dcsw_out/dt  = -mupos*csw_out+prof6-
unimmun_cli  unprof6+art_csw_out-art_csw  unout-res  csw  out
Initial Value = 0.0  Initial Value = 0.0
cIl  late  rl  csw_prog
dcli_late.rl/dt = -muposscliilate_rl+custom7-  dcsw_prog/dt  = -mupos*csw_prog+prof5-
uncustom7+pro__cli_r-aids_cli_rI  unprof5+artncsw_prog-art_csw_unprog-res_csw_prog
Initial Value = 0.0  Initial  Value = 0.0
cil  late  r2  csw_uninf
dcli_late  r2/dt = -mupos*cli_late_r2+custom8-  dcsw_unmnf/dt=-muneg*csw  uninf+profl-unprofl-
uncustom8+res_cliprog+res_cli_out-aids_clihr2  inf  csw_r-inf_csw_s-immun  csw+unimmun_csw
Initial Value = 0.0  Initial Value =- initpop  female'init_frac_csw*(l-
initinf csw)
ciI  late_s
dcli_late_s/dt = -mupos*cli_late_s+custom4-  cum_incidence
uncustom4+pro  cli  s-art  cli_prog+art_cli_unprog-  dcum  incidence/dt = incidence
art  cli  out+art_cli_unout-aids_cli_s  Initial Value = 0.0
Initial Value =
init_pop_male*init_frac_cli*init_inf  cli*hivprog/(aidsrate+  fem  early  r
hivprog)*hivprog/(hivprog+uncust)  dfem_early_r/dt=-mupos'fem  earlyr-
prof3+unprof3+inf  fem  r-pro_fem_rr+inf  fem_immun_r
ciI_out  Initial Value = 0.0
dcli  out/dt = -mupos*cli_out+custom6-
uncustom6+art_cli_out-art_cli_unout-res_cli_out  fem_early_s
Initial Value = 0.0  dfem  early_s/dt = -mupos*fernearly_s-
prof+2unprof2+inf  fern  s-pro  femrs+inf_ferr_immun_s
c_lprog  Initial  Value= init_pop_female*(l-
dcli_prog/dt =-mupos*cli_prog+custom5-  init  frac  csw)*init  inf  fem'aidsrate/(aidsrate+hivprog)
uncustom5+artcli_prog-art_cliunprog-res_cli_prog
Initial  Value = 0.0  fem-immun
dfernimrnun/dt=-muneg*fem  immun+unprofO-
cIl_unlnf  profO+immun_fem-inf_fern_immun  r-inf  fernimmun  a-
dcli_uninf/dt = -muneg*cli_uninf+customrl-uncustomrl-  unimmun_femr
inf cli_r-inf  cli_s-imnun_cli+unimmun_cli  Initial Value  = 0.0
Initial Value = init_pop  maleinit_frac_cli'(l-int_inf_cl)
fem_late  rI
csw_early_r  dfem_late_rl/dt = -mupos*fernmlate_rl-
dcsw_early_r/dt  = -mupos*csw_early  r+prof3-  prof7+unprof7+pro_fern_r-aids_fem_rl
unprof3+inf csw_r-pro_csw_r+inf_csw_immun_r  Initial Value =  0.0
Initial Value = 0.0
fem_late_r2
20dfem_late_r2/dt  = -mupos'fem_late_r2-
prof8+unprof8+res_fem_prog+res_fem_out-aids_fern_r2  men-out
Initial Value = 0.0  dmen  out/dt = -mupos*men_out-
custom6+uncustom6+art_men_out-art_men_unout-
femr_late_s  res_men_out
dfem_late_s/dt  = -muposfem_late_s-  Initial Value = 0.0
prof4+unprof4+pro_fem_s-art_fem_prog+art_fem_unprog-
art_femr_out+art_femr_unout-aids_fem_s  men-prog
Initial Value = init_pop_female*(l-  dmen_prog/dt = -mupos'men_prog-
init_frac_csw)*init_inf  femrhivprog/(aidsrate+hivprog)  custom5+uncustom5+art_men_prog-art_men_unprog-
res_men_prog
fem  out  Initial  Value = 0.0
dfem  out/dt = -mupos*fern_out-
prof6+unprof6+art  fem_out-art_fem_unout-res_fem_out  men_uninf
Initial Value = 0.0  dmen_uninf/dt = -muneg'men  uninf-customl+uncustoml-
inf_men_r-inf  men_s+population*malegr-
femprog  immun_men+unimmun_men
dfem_prog/dt = -mupos'fem_prog-  Initial  Value = init_pop_male(l-init_fracrcli)*(l-
prof5+unprof5+art_fem_prog-art_fem_unprog-  init_inf_men)
res_fem_prog
Initial Value = 0.0  prog_recr
dprog_recr/dt=
fem  uninf  art_men_prog+art_cli_prog+art_csw_prog+art_fem_prog
dfem_uninf/dt  = -muneg*fem_uninf-profl+unprofl-  Initial Value = 0.0
inf fem_r-inf_femrs+population*femgr-
immun  fem+unimmun_fem  wild  recr
Initial  Value = init_pop_female*(l-init  frac_csw)*(l-  dwild_recr/dt =
init  inf  fem)  art_men  out+art_cli_out+art_csw_out+art_fem_out




Initial Value  = O.O  Movements between compartments
Inf  kids  aids_cli_rl
dinf kids/dt = +inf births-hivdying_kids  Flow from cli_late_ri  to AIDS_male
Initial Value =0.0  aids_cli_rl = aidsrate *  cli_late_rI
men  early_r  aids  ell  r2
dmen  early  r/dt = -mupos*men  early_r-  Flow  from cli_late_r2 to AIDS  male
custom3+uncustom3+inf  men  r-  aids  cl i r2 = aidsrate *  cl i_late_r2
pro  men_r+inf  men_immun_r
Initial Value = 0.0  aids  cil  s
Flow from cli  late  s to AIDS_male
men_early_fs  aids_cli_s = aidsrate  *  clihlate  s
dmen  early_s/dt =-mupos*men  early  s-
custom2+uncustom2+inf  men_s-  aids_csw_rl
pro  men_s+inf_men_immun_s  Flow from CSW_late_rl  to AIDS  female
Initial Value  init_pop_male'(l-  aidsacsw_rI  = aidsrate *  csw_late_rI
init_frac_clh)'init_inf_men*aidsrate/(aidsrate+hivprog)
aidsacsw-r2
men _lmmun  Flow from CSW  late  r2 to AIDS  female
dmen  immun/dt = -muneg*men  immun-  aids_csw_r2 = aidsrate *  csw_late_r2
customO+uncustomO+immun_men-inf  men_immun_r-
inf men  immun_s-unimmun  men  aids  csw_s
Initial Value = 0.0  Flow from CSW  late  s to AIDS  female
aids_csw_s = aidsrate ' csw  late  s
men_late_rl
dmen  late  rl/dt=-mupos*men  late  rl-  aids  fem  rl
custom7+uncustom7+pro  men  r-aids  men  rl  Flow from femrlate  rI  to AIDS  female
Initial  Value=  0.0  aids  fem  rI  = aidsrate *  fem  late  rl
men  late  r2  aIds_fern_r2
dmen  late  r2/dt = -mupos'men  late_r2-  Flow from  fem-late-r2 to AIDS_female
custom8+uncustom8+res_men_out+res_men_prog-  aids_fem_r2  = aidsrate ' fem_later2
aids_men  r2
Initial Value =  0.0  aids  fem  s
Flow from fem  late  s to AIDS_female
men  late  a  aids_femrs  = aidsrate * femrlate_s
dmen_late  s/dt = -muposrmen  late  s-
custom4+uncustom4+pro_men  s-  aids  men  rl
arnmen_prog+art_men_unprog-  Flow from men_late_rI  to AIDS_male
art_men  out+art_men_unout-aids_men_s  aids_men_rI  = aidsrate *  men_late_rI
Initial Value = init_pop_male'( I -
init_frac_cli)'init_inf  men'hivprog/(aidsrate+hivprog)  aids_men_r2
21Flow from men_late_r2 to AIDS_male  customl
aids_men_r2  = a idsrate *  men_late_r2  Flow from men_uninf to cli_uninf
customl  = cust' men_uninf
aids_menas
Flow  from men_late_s to AIDS_male  custom2
aids_men_s  = aidsrate * men_late_s  Flow from men_early_s to cli_early_
custom2  = cust' men  early_s
art_cil  out
Flow from cli_late_s to cli_out  custom3
art_cli_out = recr_cli_out *  cli_late_s  Flow from men_early_r to cli_early_r
custom3  = cust *  men_early  r
art_cli_prog
Flow from cli_late_s to cli_prog  custom4
art_cli_prog  = recr_cli_prog  *  cli_late  s  Flow from men_late_s  to cli_late_s
custom4  = cust *  men_late_s
art cli_unout
Flow from cli_out to cli_late_s  custom5
art_cli_unout  = outloss *  cli_out  Flow from men_prog to cli_prog
custom5  = cust *  men_prog
art_cli_unprog
Flow from ch_prog to cli_late_s  custom6
art_ch_unprog = progloss  cli_prog  Flow from men_out to cli_out
custom6 = cust *  men_out
art csw  out
Flow from csw_late_s to csw_out  custom7
art  csw_out = recr_CSW_out *  csw  late_s  Flow from men_late_rl  to cli_late_rl
custom7 = cust' men_late_rI
art_csw_prog
Flow from  csw_late_s to csw_prog  custom8
art_csw_prog = recr_csw_prog  *  csw_late  s  Flow from men_late_r2 to cli_late_r2
custom8 = cust *  men_late_r2
art_csw_unout
Flow from CSW_out to csw_late_s  hivdying_females
art_csw_unout  = outloss *  csw_out  Flow from AIDS_female to hivdeaths
hivdying_females = round(muaids *  AIDS_female)
art_csw_unprog
Flow from csw_prog to csw_late_s  bivdying_kids
art_csw_unprog  = progloss ' csw_prog  Flow from lnf_kids to hivdeaths
hivdying_kids  = round(muhiv_kids ' inf_kids)
art_fem_out
Flow from fem_late_s  to fem_out  hivdying_males
art_fem_out  = recr_fem_out *  fem_late_s  Flow from AIDS_male  to hivdeaths
hivdying_males = round(muaids'  AIDS-male)
art_fem_prog
Flow from fem_late_s to fem_prog  Immun_cli
art  fem_prog  = recr_fem_prog  *  fem_late  s  Flow from cli_uninf to cli_immun
immun_cli = vactake'vacrate_cli'cli_uninf
art_fem_unout
Flow from fem_out to fem_late_s  Immun_csw
art_fem_unout  =  outloss *  fem_out  Flow from  csw_uninf to csw  immun
immun_csw = vactake'vacrate_csw'csw_uninf
art_fem  unprog
Flow from fem_prog to fem_late_s  Immun  fem
art_fem_unprog  = progloss '  fem_prog  Flow from  femr_uninf to fem_immun
immun_fem = vactake'vacrate_fem'  fem_uninf
art_men_out
Flow from men_late_s to men_out  Immun  men
art_men_out = recr_men_out ' men_late_s  Flow from men_uninf to men_immun
immun_men = vactake'vacrate_men'men_uninf
art_men_prog
Flow from men_late_a  to men_prog  lnf_citlImmun_r
art_men_prog  = recr_men_prog *  men_late_s  Flow from cli_immun  to cli_early_r
inf  cli_immun_r = vaceff'(cli_immun'cr*fmrisk'unprot  '
art_men_unout  (wI'csw_earlyr+  w2'csw_late_rl +  w2'counsel_csw'(1-
Flow from men_out to men_late_s  sustrans)'csw_late_r2) / csw)
art_men_unout = outloss *  men_out
Inf clilImmun  s
art_men_unprog  Flow from cli_immun to cli  early_s
Flow from men_prog to men_late_s  inf_cli_immun_s  = vaceff*(cli  immun*cr*fmrisk*unprot  '
art_men_unprog = progloss ' men_prog  (wI'csw_early_s +  w2'csw_late_s +
w2'counsel_csw'sustrans'csw_late_r2  +
customO  w2'resid_infect'csw  out) / csw)
Flow from men_immun to cli_immun
customO = cust ' men  immun  Inf_cit_r
Flow from cli_uninfto cli_early_r
22inf cli  r= STD_control'(cli  uninf'cr'finrisk'unprot'  w2'resid  infect'cli_out +  wl'men  early  s +
(wl'csw_earlyr +  w2'csw_latejrl  +  w2'counsel_csw'(l-  w2'men_late_s +  w2'counsel_men'sustrans*men_late_r2
sustrans)'csw  late  r2) / csw)  +  w2'resid  infect'men  out) ' fem  uninf/fem
+fem  uninP'stabfactor'mfrisk'marrate2'
Inf_cll_s  (wl'mnen  early_s +  w2'men_late_s +
Flow from cli_uninf to cli  early  s  w2'counsel_men'sustrans'men  late_r2 +
inf  cli  s = STD_control'(cli  uninf'cr'finrisk'unprot'  w2*resid_infect'men  out) / men))
(wl'csw  early_s +  w2'csw  late_s +
w2'counsel  csw'sustrans'csw  late  r2 +  Inf_men_immun_r
w2'resid  infect'csw  out) / csw)  Flow from men_immun to men  early_r
inf  men  immun  r = vaceffP(  (leak'(wl'csw  early  r+
lnf_csw_immun_r  w2*csw  late rl +w2'counsel  csw'(l-
Flow from csw  immun to csw_early_r  sustrans)'csw_late_r2 +  wl'fem  early  r +
inf  csw_immun_r = vaceff'(csw_immun  w2'fem_late_rl+ w2'counsel_fem'(l-
'annualCSWcontacts'mfrisk'unprot  *  (wl 'cli  earlyr +  sustrans)'fem  late  r2) ' men_immun/men+
w2'cli  late  rl +w2'counsel  cli'(l-sustrans)'cli_late  r2)/  men_immun'stabfactor'finrisk'marrate * (wl'fem  early  r
clients)  +  w2'fem  late  rI +  w2'counsel_fem'(l-
sustrans)'fem  late  r2) / femr))
lnf csw  Immun s
Flow from csw_immun  to csw_early  s  Inf men_immunas
inf csw  immun_a  = vaceffP(cswimmun  Flow from men  immun to men  early  a
'annualCSWcontacts'mfrisk'unprot  * (wl'cli  early_s +  inf  men immun  s = vaceffP (leak'(wl 'csw_early  s +
w2'cli  late  s+w2'counsel_cli'sustrans'cli_late_r2  +  w2'csw_late_s +  w2'counsel  csw'sustrans'csw  late  r2 +
w2'resid_infect'cli  out)/ clients)  w2'resid-infect'csw_out+  wl'fem  early  s+
w2*fem_late_s+w2'counsel  femrsustrans*fem_late_r2  +
inf  esw  r  w2'resid  infect'fem  out) *  men_immun/men+
Flow from csw  uninf to csw  early_r  men_immun'stabfactor'fmrisk'marrate'
inf csw_r = STD_control*(csw_uninf  (wl'fem  early-s +  w2'fem  late_s
'annualCSWcontacts'mfrisk'unprot  * (wl'cli  early  r +  +w2*counsel-fem'sustrans*fem_late_r2  +
w2'cli  late  rl +w2*counselcli*(l-sustrans)'cli_late  r2)/  w2'resid_infect'fem  out) / fem)
clients)
Inf_men_r
inf caw  s  Flow from men  uninf to men_early_r
Flow from csw_uninf to csw  early  s  inf  men_r= STD  control'( (leak'(wl'csw  early_r+
inf csw_s = STD_control'(csw_uninf  w2'csw  late  rl +  w2'counsel_csw'(l-
'annualCSWcontacts'mfrisk'unprot  *  (wI 'cli  early  s+  sustrans)*csw_late_2 +  wI 'fem  early  r+
w2'cli  late_s +w2*counsel_cli'sustrans'cli_late_r2  +  w2*fem_late_rl+  w2*counsel_fem*(l-
w2'resid  infect'cli_out) / clients)  sustrans)*feml_ate  r2) * men_uninf/men+
men_uninf'stabfactor'fmrisk*marrate  *  (w I  'fem  early  r
Inf_femr_immun_r  +  w2*fem_late  rl +  w2'counsel_fem'(l-
Flow from fem_immun to fem_early_r  sustrans)'fem  late  r2) / femr))
inf fem  immun_r = vaceff* (leak'(wl 'cli_early  r +
w2'cli  late_rl + w2'counsel_cli'(1-sustrans)'cli_late_r2  +  inf_men_s
w1lmen  earlyr +  w2*men_late_rl+  w2*counsel_men'(l-  Flow from men_uninf to men  early  s
sustrans)*men  later2)* fem  immun/fem +  inf  men_ s=STD  control*((leak*(wl*csw  early  s+
fem  immun*stabfactormfrisk'smarrate2'  w2'csw  late  s +  w2*counsel_csw'sustrans'csw_late_r2 +
(wl'men early  +w2'men_late_rl+  w2'resid_infect'csw_out+  wl'fem  early  +
w2'counselrmen'(l-sustrans)'men_late  r2) / men)  w2'femrlate_s+w2'counsel-fem*sustrans*fem_late_r2  +
w2*resid  infect*fem  out) *  men  uninf/men+
Inf fem  rimmun_s  men_uninf'stabfactor'fmrisk*marrate  *  (wlIfem  early  s
Flow from fem_immun to fem_early_s  +  w2'fem_late_a  +w2'counsel_fem'sustrana'fem_late_r2
inf  fem  immun  s=vaceff'(leak'(wl'cli  early  s+  +  w2'resid_infect'fem  out) / fem))
w2*cli late  s +  w2'counsel  cli'sustranscli  late r2 +
w2'resid  infect*cli  out+wl'men_early  s+  pro  cl  ir
w2*men  late  s + w2*counselmen*sustransmen  late_r2  Flow from cli  early  r to cli  late  rl
+  w2'resid  infect'men  out) * femr  immun/fem  pro cir  = hivprog *  cli  early  r
+fem_immun'stabfactor'mfrisk'marrate2'
(wl'men  early_s +  w2'men_late_s +  pr_ecll_s
w2*counsel  men'sustrans*men  late  r2 +  Flow from cli  early  s to cli  late  s
w2*resid_infect'men  out) /  men-)  pro_cli_s = HlVprog *  cli  early  s
lnf_femr_r  pro_awrj
Flow from femruninf to femr  early  r  Flow from CSW  early  rto CSW_late_rI
inf  fem r= STD control'( (leak'(wl  'cli  early  r +  pro_cswr  =  hivprog 'cswearly_r
w2'cli  late_ri +  w2'counsel  cli'(l-sustrans)'cli_late_r2  +
wl'men_earlyr +  w2'men_late_rl+  w2'counsel_men'(l-  pro  csw  a
sustrans)'men  iate  r2) *  femn_uninf/fem  +  Flow from CSW  early  s to CSW_late_s
fem  uninf'stabfactor'mfrisk'marrate2  ' (wl 'men  early_r  pro  csw  s = HlVprog 'csw  early  s
+  w2'men  late_rl+ w2'counsel_men*(l-
sustrans)*men  late  r2) / men))  pro_fem_r
Flow from fem  early_r to femrlate_rI
Inf fem  rs  pro  fem  r= hivprog *  fem  early_r
Flow from fem  uninf to fem  early  s
inf  fem  s = STD_control'((leak*(wl'cli  early  s+  pro  ferns
w2'cli_late_s +  w2*counsel_cli'sustrans*cli_late_r2  +  Flow from  fem_early_s to fem_late_s
23pro_fem_s = HlVprog *  fem_early_s
res_men_out
pro  men_r  Flow from men_out to men_late_r2
Flow from men_early  r to men_late_ri  resamen_out = outRDR *  men  out
pro  men_r = hivprog *  men_early_r
resmen_prog
pro_men_s  Flow from men_prog to men  late  r2
Flow from men_early_s  to men_late_s  res  men  prog = progRDR *  men_prog
pro  men_s = HlVprog *  men_early_s
uncustomO
profO  Flow from cli_immun to men_immun
Flow from femrimmun to csw_immun  uncustomO  = uncust *  cli-immun
profO = prof* exp(annualCSWcontacts/1000-1)  *
fem_immun  uncustoml
Flow from cli  uninf to men_uninf
pronl  uncustoml  = uncust*  cli_uninf
Flow from femruninf to csw_uninf
profl = prof  femruninfexp(annualCSWcontacts/1000-1)  uncustom2
Flow from cli_earlyYs  to men_early_a
prof2  uncustom2 = uncust *  cli_early  a
Flow from femrearly_s to csw_early_s
prof2 = prof'  fem_early_*exp(annualCSWcontacts/l  OOO-  uncustom3
I)  Flow from cli_early_r  to men_early_r
uncustom3  = uncust *  cli_early  r
prof3
Flow from femrearly  r to CSW_early_r  uncustom4
prof3 =prof*  fem_early_r*exp(annualCSWcontacts/1000-  Flow from cli_late_a  to men  lates
I)  uncustom4 = uncust *  cli_late-s
prof4  uncustom5
Flow from femrlate_s to CSW_late_s  Flow from cli  prog to men_prog
prof4 = prof* exp(annualCSWcontacts/1000-1)  *  uncustom5  = uncust *  cliprog
fem_late_s
uncustom6
prof6  Flow from cli  out to men_out
Flow from fem_prog to CSW_prog  uncustom6 = uncust *  cli_out
prof5 = profexp(annualCSWcontacts/1000-1)  *  fem_prog
uncustom7
prof6  Flow from cli  late_ri  to men  late  rl
Flow from femrout to CSW_out  uncustom7  = uncust *  cli_late_ri
prof6 = prof'exp(annualCSWcontacts/1000-1)  *  fem_out
uncustom8
prof7  Flow from cli  late_r2 to men  late_r2
Flow from femrlate_rI  to CSW_late_rI  uncustom8 = uncust *  chllate_r2
prof7 = prof*exp(annualCSWcontacts/1000-1)  *
fem_late_rl  unimmun_cli
Flow from cli_immun  to cli_uninf
prof8  unimmun_cli = losstimmun *  cliiimmun
Flow from femrlate  r2 to CSW_late_r2
prof8 = prof*exp(annualCSWcontacts/l OOO-I)  *  unimmun_esw
fem_late_r2  Flow from csw_immun  to csw_uninf
unimmun_csw = loss_immun*  csw_immun
res_cil_out
Flow from cli_out to cli_late_r2  unimmun  fem
res_cli_out = outRDR *  cli_out  Flow from fern_immun to fem  uninf
unimmun_femr  loss_immun  *  femrimmun
res_cll_prog
Flow from cli_prog to cli_late_r2  unimmun_men
res_clijprog = progRDR *  cli  prog  Flow from  men_immun to men  uninf
unimmun_men  - loss_immun *  men_immun
res_esw_out
Flow from csw_out to csw_late_r2  unprofO
res_csw_out  = outRDR *  csw_out  Flow from csw_immun  to fem  immun
unprofO = unprof *  csw_immun
rescw_prog
Flow from csw_prog to csw_late_r2  unprofi
res_csw_prog = progRDR  *  csw_prog  Flow from csw_uninf to fem  uninf
unprofl = unprof* csw_uninf
res_fern_out
Flow from fern_out to fem_late_r2  unpro12
res_femrout = outRDR *  fem_out  Flow from CSW_early_s to fem  earlys
unprof2 = unprof* csw_early_s
res_femprog
Flow from fem_prog to femr_late_r2  unproB3
res_fem_prog  = progRDR *  fem  prog  Flow from CSW_early_r to femrearly_r
24unprof3  = unprof ' csw_early_r  female_prev_res =
(esw_late_rl+csw_late_r2+fem_late_rI  +fem_late_r2+csw_
unprof4  early  r+fem_early_r)/females
Flow from CSW  late_s to fem_late_s
unpromf4  = unprof ' cswlate_s  female_prevalence
female_prevalence = (females-femruninf-csw_uninf-
unprof6  femrimmun-csw_immun)/females
Flow from CSW_prog to fem_pmg
unprof5 = unprof *  csw_prog  females
females  = fem+csw
unprof6
Flow from CSW  out to fem  out  In  outl
unprof6 = unprof  csw_out  In_outl  = fem_out+men_out+csw_out+cli_out
unprof7  In-out2
Flow from CSW  late_ri  to fem_late_ri  In_out2  = femrout+men_out+csw_out+cli_out+(l-
unprof  = unprof '  csw_late_ri  old_femnpp)*fem_late_r2+( I-
old  men_pp)'men_late  r2+(I-
unprofg  old  csw_pp)'cswjlate_r2+(1-old_cli_pp)'cli_late_r2
Flow from CSW_late_r2 to femrlate_r2
unprof8 = unprof *  csw_late_r2  In_progl
Inprogl = fem_pmg+men_pmg+csw_prog+cli_prog
VARIABLES  In_prog2
Variables defined in terms of  fem-progmen_pmg+csw_pmg+cli_pmg+old2fem_pp*fe
compartments, flows etc in the model  m_late_r2+old_men_pp*men_late_r2+old_csw_pp*csw_lat
e_r2+old_cli_pp*cli_ate_r2
aids_dead
aids  dead =  Incidence
hivdying-females+hivdying_males+hivdying  kids  incidence=
round(inf cli_immun_s+inf  csw_immun_s+inf_men_imm
annualCSWcontacts  un_s+inf_fem_immun_s+inf_cli_immun_r+inf_csw_immu
annualCSWcontacts  = cr'clients/csw  i_rmnf_men_immun_r+inf  fern_immun_r-i-
inf cli_s+inf  csw_s+inf  men_s+inf fem_s+inf  cli_r+inf c
cll_prop_prog  sw_r+inf  men_r+inf  femrr+inf  births)
cli_prop_prog =
res_cli_prog/(res_cli_prog+res_cli_out+O.OOOI)  Inf  births
inf births = round(brate*vtrate*(
clients  w I  csw_early_r+w I  fem  early_r+(wl *csw_early_s+w2*c
clients=  sw_late_s+wl *femearlys+w2*fem  late_s)*(nevirapine_r
cli_immun+cli_early_s+cli  late  s+cli  uninf+cli_prog+cli  I  ate*nevirapine  effect+(l- nevirapine rate))+(csw_prog+femjges_ut+e_ut ate  rl+cli  late  r2+cli  out+cli  earlyr  )wtnevirapine_re))+(cs w  latem+fem_  lout+femr  ot
- - - - ~~~-  -I  )'w2'nevirapine_effect+w2*(csw_1atc_rl  +fem_late_rl +cs
counsel_cil  w_late_r2+femJ_ate_r2)))
counsel  cli = (I-old_cli_pp)+old  cli_ppecounseI  maie_prevres
counsel  csw  male_prevres=
counsel  csw= (-old  csw_p)+old  cswppeounselcsw  (cli  late  rl+cli  late_r2+men_late  rl+men_late_r2+cli_earl
y_r+men_early_r)/males
counsel_rem
counsel  fem=(1 -old  fempp)+old  fem_ppcounsel  male_prevalence
- -P  M-PP  male_prevalence  = (males-cli  uninf-men_uninf.
counsel_men  men_immun-cli  immun)/males
counsel  men = (I -old  men_pp)+old  men_pp'counsel  males
asw  males = men+clients caW
csw =
csw_immun+csw  early_s+csw  late_s+csw  uninf+csw_pm  marrmte2




rescswprog(rescsw_rog+res  csw out+O.OOOI)  men_immun+men  early_s+men_late_s+men_uninf+men_I
ate_rl+men_late  r2+men_prog+men_early_r+men  out
fem
fem =  men_prop_prog
fem_immun+fem_early  s+fem_late_s+fem_uninf+-fem  late  men_propprog=
rl+fem  late  r2+fem_prog+fem  early  r+fem  out  resmen_prog/(res_men_prog+res_men_out+O.OOO  I)
fem_prop_prog  milpop
fem_prop_prog =  milpop = population/1000000
res_femprog/(res_fem_prog+res_fem_out+O.OOO  I)  non_vaccnated
female_prev_res
25non_vaccinated =  1-
(men  immun+cli_immun+csw_immun+femrnimun)/(men
_immun+cli  immun+csw_immrun+fem_immun+men_uninf  DELAYS
+cli_uninf+csw_uninf+fem  uninf)  Time-lagged variables
population
population = round(males+females)  oid_  ei_pp
Delay  =1.5
prev  CSW  Initial Value = 0
prev  CSW = (csw-csw_uninf-csw_immun)/csw  Maximum Delay = 1.7
preval_res  old_esw_pp
preval_res  =  Delay =  1.5
(males*male_prev_res+females*female_prevres)/(males+f  Initial Value = 0
emales)  Maximum  Delay = 1.7
prevalence  old_fem_pp
prevalence  =  Delay=  1.5
(males*male_prevalence+females*female_prevalence)/(mal  Initial Value = 0
es+females)  Maximum  Delay = 1.7
prim  resistant  old_men_pp
prim  resistant =  Delay =  1.5
(csw  early_r+csw_late_rl+fem_early_r+fem_late_rl+clihe  Initial Value = 0
arly_r+cli_late_rl+men_early_r+men_late_rl)/(population*  Maximum  Delay = 1.7
prevalence)
prop_elient  DEFINE VALUES
prop_client = clients/mates  Variables  influenced by interventions
cr
propesw  cr=
prop_csw = csw/females  cr = cr_before
prop_inf  births  nevirapine  rate
prop  inf births =  inf_births/(brate*females)  nevnrapinmerate  = 0
prop.males  reer_cli_out
prop_males = males/population  recr_clibout  = 0
resistant  recr._ecl_prog
resistant =  recr_cli_prog  = 0
(csw  early_r+csw_late_rl+csw_late_r2+fem_early_r+fem
late_rl+fem_late_r2+cli_early_r+cli_late_rl+cli_late_r2+m  recr_CSW  out
en_early_r+men_late_rl+men  late_r2)/(population*prevale  recr_CSW_out = 0
nce)
recr_csw_prog
vacrate  cli Conditional  recrcsw_prog  = 0
vacrate_cli  =
0.75 for t>startyr_vaccin+2  recr_fem_out
0.75 for t>startyr_vaccin  recr_fem_out = O
0 by default
recr_fem_prog
vacrate_csw  Conditional  recr_fem_prog = 0
vacrate_csw =
0.75 for t>startyr_vaccin+2  recr_men_out
0.75  for t>startyr_vaccin  recr_men_out  = 0
0 by default
reer_men_prog
vacrate  fem Conditional  recr_men_prog = 0
vacrate_fem =
0 for t>startyr_vaccin+2  STDlcontrol
0 for t>startyr_vaccin  STD_control  = I
0 by default
unprot
vacrate  men Conditional  unprot = unprot_before
vacrate_men  =
0 for t>startyr_vaccin+2
0 for t>startyr_vaccin  INDEPENDENT  EVENTS
0 by default  Interventions
STD_.prog
year  Non-periodic  triggers at:
year = t+ 1998  startyr_std
Actions:
STD_control = STD  effect;
26Introd_art
Non-penrodic  triggers at:





recr_cli_out  = art_out_effect;
Inter_AART_pop







recr_fem_out  = gen_prog_efftart_out_effect;




startyr  art  csw
Actions:
recr  csw prog = recr  csw_rog_effect;
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